October 24, 2024

Uncategorized

New Releases from NCBI BookshelfCapivasertib (Truqap): Indication: Capivasertib is indicated in combination with fulvestrant for the treatment of adult females with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy: CADTH Reimbursement Recommendation [Internet].​Capivasertib (Truqap): Indication: Capivasertib is indicated in combination with fulvestrant for the treatment of adult females with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy: CADTH Reimbursement Recommendation [Internet].

CADTH recommends that Truqap in combination with fulvestrant should be reimbursed by public drug plans for the treatment of adults

Uncategorized

New Releases from NCBI BookshelfRemdesivir (Veklury): Indication: For the treatment of coronavirus disease 2019 in nonhospitalized adults and pediatric patients (weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization and death: CADTH Reimbursement Recommendation [Internet].​Remdesivir (Veklury): Indication: For the treatment of coronavirus disease 2019 in nonhospitalized adults and pediatric patients (weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization and death: CADTH Reimbursement Recommendation [Internet].

CADTH recommends that Veklury be reimbursed by public drug plans for the treatment of COVID-19 in adults who are not

Scroll to Top